Novel antibiotic Gepotidacin safe, tolerable and effective option against UTI: Lancet

In a recent study, a novel antibiotic, the Gepotidacin has demonstrated promising efficacy and safety in clinical trials against urinary tract infections (UTIs). Gepotidacin was developed as a first-in-class triazaacenaphthylene antibiotic and it works by inhibiting bacterial DNA replication through a unique mechanism of action. The findings were published in The Lancet Journal.

The two Phase 3 trials, EAGLE-2 and EAGLE-3 were conducted on adolescent and adult females with uncomplicated UTIs and compared the efficacy and safety of oral Gepotidacin with that of nitrofurantoin which is commonly prescribed antibiotic for UTIs.

The participants in the trials received either oral Gepotidacin or nitrofurantoin for five days and the results showed that Gepotidacin was non-inferior to nitrofurantoin in both studies. In EAGLE-3, the Gepotidacin expressed superiority over nitrofurantoin and highlighted its potential as a potential option for UTI treatment.

Gepotidacin demonstrated a well-balanced inhibition of two type II topoisomerase enzymes that makes it effective against a wide range of bacterias causing UTI, including the drug-resistant strains. Despite its efficacy, the safety profile of Gepotidacin remained favorable. The most common adverse event associated with Gepotidacin was diarrhea, that was observed in a small percentage of patients, while nausea was the predominant adverse event with nitrofurantoin. Also, all adverse events were mostly mild or moderate, with no life-threatening occurrences being reported.